Terns Pharmaceuticals, Inc.
TERN
$52.63
$0.070.13%
NASDAQ
Corporate Info
Website
Phone Number
650 525 5535
Address
1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
Suite 100
Foster City, CA 94404
Country
United States
Year Founded
2016
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
Business Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.